Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action.

Nonalcoholic fatty liver disease or metabolic-associated fatty liver disease (MAFLD) is a common condicion with increasing prevalence and incidence, specially in patients with type 2 diabetes mellitus (T2DM). Both cardiovascular and renal disease are clearly increased in these patients, particularly in those with diabetic nephropathy. In the liver-heart-kidney-metabolic axis, the common pathophysiological basis of MAFLD, cardiovascular disease (CVD), chronic kidney disease (CKD), and T2DM is the same. The clinical relationship between all of them is clear and is multidirectional: MAFLD may precede the development of cardiovascular and renal disease, and may also worsen the prognosis of these complications once developed. In this review we emphasize the importance of targeting MAFLD in Diabetic kidney disease, with the goal of detecting high-risk patients in order to improve their prognosis.

Esteatosis hepática metabólica y nefropatía diabética: una llamada a la acción / Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action

La incidencia y la prevalencia de hígado graso no alcohólico o enfermedad hepática metabólica (EHmet) está en aumento y es mayor en pacientes con diabetes mellitus tipo 2 (DM2). El riesgo cardiovascular y renal está claramente incrementado en estos pacientes, especialmente cuando se desarrolla nefropatía diabética. El eje cardio-reno-hepato-metabólico, conformado por la enfermedad cardiovascular (ECV), la enfermedad renal crónica (ERC), la EHmet y la DM2, tiene una base fisiopatogénica común. La relación clínica entre todos los componentes es inevitable y multidireccional, pudiendo la EHmet preceder al desarrollo de complicaciones cardiovasculares y renales, y también empeorar el pronóstico de las mismas una vez desarrolladas. En esta revisión enfatizamos la importancia de buscar y tratar la EHmet en pacientes con ERC y DM2 con el objetivo de identificar pacientes de mayor riesgo y de mejorar su pronóstico.(AU)

Non-alcoholic fatty liver disease or metabolic-associated fatty liver disease (MAFLD) is a common condition with increasing prevalence and incidence, specially in patients with type 2 diabetes mellitus (DM2). Both cardiovascular and renal disease are clearly increased in these patients, particularly in those with diabetic nephropathy. In the liver–heart–kidney–metabolic axis, the common pathophysiological basis of MAFLD, cardiovascular disease (CVD), chronic kidney disease (CKD), and DM2 is the same. The clinical relationship between all of them is clear and is multidirectional: MAFLD may precede the development of cardiovascular and renal disease, and may also worsen the prognosis of these complications once developed. In this review we emphasize the importance of targeting MAFLD in diabetic kidney disease, with the goal of detecting high-risk patients in order to improve their prognosis.(AU)

Probable interacción farmacológica entre sulfonilurea y betabloqueante en paciente con DM-II. Un reporte de caso / Probable pharmacological interaction between sulfonylurea and beta blocker in patients with DM-II. A case report

El estudio presenta el caso de una mujer de 47 años con diabetes tipo 2 (DM-II), hipertensión y anemia, tratada con metformina, glibenclamida, metoprolol y hierro/ácido fólico. Se identificó una interacción farmacológica entre glibenclamida y metoprolol, causando síntomas de hipoglucemia por la tarde. La evaluación mediante la Escala de Probabilidad de Interacciones Farmacológicas (EPIF) de Horn sugirió una interacción probable. El análisis farmacocinético reveló que el tiempo en el cual se alcanzan las concentraciones máximas de ambos fármacos coincidía con el inicio de los síntomas. Se implementó un nuevo horario de medicación que resolvió los síntomas. La interacción farmacológica se atribuyó al bloqueo de los efectos adrenérgicos por el metoprolol, comprometiendo la capacidad de contrarrestar la acción de la insulina liberada por la glibenclamida. Se resalta la importancia de la vigilancia, la toma de decisiones informadas y la implementación de estrategias preventivas para garantizar la seguridad y eficacia del tratamiento farmacológico en pacientes con condiciones clínicas específicas, como la DM-II y enfermedades cardiovasculares concomitantes.(AU)

[Evaluation of healthcare for patients with diabetes in primary care: A systematic review]. / Evaluación de la asistencia sanitaria del paciente con diabetes en atención primaria: una revisión sistemática.

OBJECTIVE: Have the most current evidence in relation to the evaluation of medical healthcare for patients with diabetes in primary care. METHOD: During the review process, we followed the recommendations to improve the publication of systematic reviews and meta-analyses and the preferred reporting points for PRISMA systematic reviews. The bibliographic search was carried out in Cumulative Index to Nursing and Allied Health Literature (CINAHL), SCOPUS, Scielo, MedLine/ PubMed, Cochrane databases and in the Google Scholar search engine, with free and controlled language, using the MeSh search terms: «Physicians, Primary Care¼, «Diabetes Mellitus, Type2¼. Eight selected articles were analyzed. The articles were selected based on their relevance, published in peer-reviewed academic journals and published between 2019 and 2023. RESULTS: The main study tool represents interventions in knowledge and practice about the care of patients with diabetes among primary care physicians. The most important discussion topics extracted in the analyzed articles refer to knowledge, clinical inertia, patients' housing challenges, adherence intervention programs, and a self-care application for patients with diabetes. CONCLUSIONS: The findings of this study indicate the need to improve medical health care through knowledge, attitudes and practices in primary care regarding patients with diabetes. In this way, it could be considered a useful tool to promote medical healthcare in primary care.

Risk factors associated with glomerular filtration rate in Mexican adults with type 2 diabetes mellitus.

INTRODUCTION: Type 2 diabetes mellitus (T2DM) is related to glomerular filtration rate (GFR) impairment, which is one of the main causes of chronic kidney disease. The objective of this study was to identify the risk factors related to GFR in Mexican adults with T2DM, using a validated multiple linear regression model (MLRM), with emphasis in body adiposity, glycemic control, duration of the diabetes and other relevant risk factors. MATERIALS AND METHODS: A cross-sectional, analytical, and observational study was carried out in 252 adults with a previous diagnosis of T2DM. Body mass index (BMI) and waist circumference (WC) were determined and a fasting blood sample was collected for glucose, creatinine and HbA1c determinations. GFR was calculated with the Cockcroft-Gault equation adjusted for body surface area. Four MLRM were performed to determine the factors related to the GFR; it was evaluated whether these models complied with the statistical assumptions of the linear regression model. RESULTS: The average age of the participants was 60 ±â€¯12 years, 62.3% of them were women. GFR correlated with BMI and WC; age and duration of the diabetes were associated inversely. Model 4 of the MLRM reported a coefficient of determination of 53.5% where the variables BMI (ß = 1.31), male sex (ß = -6.01), duration of T2DM (ß = -0.57), arterial hypertension (ß = -6.53) and age (ß = -1.45) were simultaneously and significantly related to the GFR. CONCLUSIONS: Older age, male sex, longer duration of T2DM and the presence of arterial hypertension were associated with a decrease in the GFR; BMI and WC were directly associated. No effect of glucose and HbA1c on GFR was observed.

Validez y fiabilidad del cuestionario ARMS-e en pacientes con Diabetes mellitus tipo 2 / Validity and reliability of the ARMS-e questionnaire in patients with type 2 Diabetes mellitus

Introducción: El cuestionario “Adherence to Refills and Medications Scale” (ARMS) se diseñó para medir adherencia al tratamiento. Fue traducido y adaptado al español, pero no se han evaluado sus propiedades psicométricas. El objetivo fue evaluar dichas propiedades en una población con diabetes mellitus tipo 2. Método: El estudio se llevó a cabo en farmacias comunitarias de Granada (España) mediante entrevista. Se realizó un análisis factorial de componentes principales (AFCP) con rotación Varimax (validez de constructo), un análisis de concordancia (validez de criterio concurrente y fiabilidad por estabilidad temporal) y alfa de Cronbach y correlación ítem-total (fiabilidad por homogeneidad). Resultados: 107 pacientes entraron en el estudio. El 54,2 % (58) fueron hombres y la edad media fue 70,5 años (D.E.: 9,7). El AFCP extrajo 4 factores que explicaron el 57,49 % de la varianza total. El alfa de Cronbach= 0,428 y el test-retest κ= 0,627 (p > 0,001). Conclusiones: El ARMS-e no puede ser considerado una herramienta útil para medir la adherencia al tratamiento antidiabético oral en esta muestra. (AU)

Introduction: The Adherence to Refills and Medications Scale questionnaire (ARMS) was designed to measure ad-herence to treatment. It was translated and adapted into Spanish, but its psychometric properties have not been evaluated. The aim was to evaluate these properties in a population with type 2 diabetes mellitus. Method: The study was carried out in community pharmacies in Granada (Spain) by interview. A principal compo-nent factor analysis (PCA) with Varimax rotation (construct validity), a concordance analysis (concurrent criterion validity and reliability by temporal stability) and Cronbach’s alpha and item-total correlation (reliability by homo-geneity) were performed. Results: 107 patients entered the study. 54.2 % (58) were male and the mean age was 70.5 (SD: 9.7). The PCA extract-ed 4 factors that explained 57.49 % of the total variance. Cronbach’s alpha= 0.428, and in the test-retest κ= 0.627 (p > 0.001). Conclusions: The ARMS-e cannot be considered a useful tool to measure adherence to oral antidiabetic treatment in this sample. (AU)

Dairy product consumption and type 2 diabetes in an Argentinian population:is there an association? / Consumo de productos lácteos y diabetes tipo 2 en una población argentina: ¿existe asociación?

Introduction: dairy products have long been recommended as part of a healthy eating plan, but there is a controversial opinion about whetheror not they should be included in the diet of people with type 2 diabetes (T2D).Objective: the aim of this study was to know if there is an association between the intake of total dairy and dairy subgroups and the chance ofhaving T2D, and the status of markers of glucose metabolism.Methods: three hundred and forty-two adult subjects participated in the study. A validated food-frequency questionnaire was applied to establishthe dairy intake. Clinical-pathological and anthropometric variables (height, weight, waist circumference and serum concentrations of blood glucose,glycated hemoglobin [HbA1c], high sensitive C-reactive protein [hs-CRP], tumor necrosis factor alpha [TNFα], interleukin [IL] 6 and IL-10) weremeasured. Consumption tertiles were calculated for each dairy subgroup. Correlation coefficients, multiple linear regression models and logisticregression models were used to assess the relation between dairy product consumption and markers of glucose metabolism.Results: a negative correlation was observed between the consumption of fermented dairy products and IL-10 (r = -0.27, p = 0.0206). Fermenteddairy products were inversely associated with blood glucose, and HbA1c. Total dairy intake was positively associated with a lower chance ofhaving diabetes in tertiles 2 and 3 of consumption, in relation to the reference tertile, adjusted for age, smoking habit, and alcohol intake, bodymass index (BMI) and dietary variables.Conclusions: with this study, we broaden our understanding of the role of dairy intake in diabetes risk. However, more long-term studies areneeded to confirm the associations and explore different confounding factors.(AU)

Introducción: los lácteos se han recomendado durante mucho tiempo como parte de un plan de alimentación saludable, pero existen opinionescontrovertidas sobre si deben incluirse en la dieta de las personas con diabetes tipo 2 (DT2).Objetivo: el objetivo fue conocer si existe asociación entre la ingesta de lácteos totales y subgrupos lácteos y la posibilidad de tener DT2, y elestado de los marcadores del metabolismo de la glucosa.Métodos: participaron 342 sujetos adultos. Se aplicó un cuestionario de frecuencia de consumo para establecer el consumo de lácteos. Semidieron variables clínicas-patológicas y antropométricas (talla, peso, circunferencia de cintura y concentraciones séricas de glucosa en sangre,hemoglobina glicosilada [HbA1c], proteína C reactiva ultrasensible [PCR-us], factor de necrosis tumoral alfa [TNFα], interleuquina [IL] 6 e IL-10).Se calcularon terciles de consumo para cada subgrupo de lácteos. Se utilizaron coeficientes de correlación, modelos de regresión lineal múltipley regresión logística para evaluar la relación entre el consumo de lácteos y los marcadores del metabolismo de la glucosa.Resultados: los productos lácteos fermentados se asociaron inversamente con la glucosa en sangre y la HbA1c. La ingesta total de lácteos seasoció positivamente con una menor probabilidad de tener diabetes en los terciles 2 y 3 de consumo, en comparación con el tercil de referencia,ajustado por edad, tabaquismo, ingesta de alcohol, índice de masa corporal (IMC) y variables dietéticas.Conclusiones: con este estudio, ampliamos nuestra comprensión del papel de la ingesta de lácteos en el riesgo de diabetes. Sin embargo, senecesitan más estudios a largo plazo para confirmar las asociaciones y explorar diferentes factores de confusión.(AU)

[Association between therapeutic adherence and phases of grief in patients with type 2 diabetes mellitus]. / Asociación entre la adherencia terapéutica y las fases de duelo en pacientes con diabetes mellitus tipo 2.

OBJECTIVE: To evaluate the association between therapeutic adherence and the phases of grief in patients with type 2 diabetes mellitus. DESIGN: Cross-sectional observational study. SITE: Family Medicine Unit No. 53 of the Mexican Institute of Social Security in the State of Guanajuato. PARTICIPANTS: A total of 354 patients with type 2 diabetes mellitus were recruited, of whom 236 corresponded to the group without therapeutic adherence and 118 to the group with therapeutic adherence. INTERVENTIONS: Two structured surveys were administered to both groups. MAIN MEASUREMENTS: The Morisky 8 scale was used to measure therapeutic adherence and the phases of grief scale (EFD-66) to measure grief due to loss of health. RESULTS: The median denial phase and depression phase scores were higher in the nonadherence group than in the adherence group (p=.000). The median negotiation phase and acceptance phase score was higher in the adherence group than in the nonadherence group (p=.000). Multivariate analysis identifies that denial is the main factor associated with non-adherence (OR=1.25; 95% CI: 1.14-1.37); while negotiation (OR=0.88; 95% CI: 0.82-0.94) and acceptance are associated with adherence (OR=0.79; 95% CI: 0.75-0.83). CONCLUSIONS: There is an association between therapeutic adherence and phases of grief.

Diabetes y apnea obstructiva del sueño. Un estudio de casos y controles / Diabetes and obstructive sleep apnoea: A case-control study

Introducción La apnea obstructiva del sueño (AOS) y la diabetes mellitus (DM) son enfermedades muy prevalentes frecuentemente asociadas. Su coexistencia se asocia de forma independiente con un aumento de la prevalencia de comorbilidades cardiovasculares. Al existir un infradiagnóstico de esta asociación, es necesario optimizar la sospecha clínica mediante el estudio de predictores independientes de DM o de prediabetes (preDM) en pacientes con AOS. Método Estudio de casos y controles, seleccionados de manera aleatoria simple y emparejados por sexo, índice de masa corporal (IMC) y edad, que pretende estudiar la asociación de la AOS con la DM y la preDM e identificar factores predictores independientes para ambas enfermedades, en las personas con AOS. Resultados Incluimos 208 casos con AOS y 208 controles, sin AOS. En los primeros, el 18,8% tenían DM, por solo el 10,1% en los segundos (p=0,00). La prevalencia de preDM fue del 41,8% vs el 10,6%, respectivamente (p=0,00). Ciento veinticuatro casos (59,6%) refirieron excesiva somnolencia diurna (ESD) (escala Epworth, 10,5±3,1) vs el 24,5% del grupo control (escala Epworth, 6,6±2,9). El índice de apnea-hipopnea (IAH) y los índices de desaturación de O2 (IDO, CT90 y CT80) fueron significativamente mayores en el grupo de casos. El riesgo de presentar DM se relacionó con la edad, la hipoxemia nocturna y la ESD. El riesgo de presentar preDM, con el IMC y con el IAH. Conclusiones La AOS se asocia a la DM y a la preDM. La edad, la hipoxemia nocturna y la ESD son predictores de DM. El IMC y el IAH lo son de la preDM. (AU)

Introduction Obstructive sleep apnoea (OSA) and diabetes mellitus (DM) are very prevalent diseases frequently associated. Their coexistence is independently associated with an increased prevalence of cardiovascular comorbidities. As this association is underdiagnosed, it is necessary to optimise clinical suspicion by studying independent predictors of DM or prediabetes (preDM) in patients with OSA. Method A simple randomised case-control study, matched for sex, body mass index (BMI) and age, aimed to study the association of OSA with DM and preDM and to identify independent predictors for both diseases in people with OSA. Results We included 208 cases with OSA and 208 controls without OSA. In the former, 18.8% had DM compared to only 10.1% in the latter (P=.00). Prevalence of preDM was 41.8% vs. 10.6%, respectively (P=.00). One hundred and twenty-four cases (59.6%) reported excessive daytime sleepiness (EDS) (Epworth scale, 10.5±3.1) vs. 24.5% of the control group (Epworth scale, 6.6±2.9). Apnoea-hypopnoea index (AHI) and O2 desaturation indices (IDO, CT90 and CT80) were significantly higher in the case group. The risk of MD was related to age, nocturnal hypoxaemia and EDS. The risk of pre-MD was related to BMI and AHI. Conclusions OSA is associated with DM and preDM. Age, nocturnal hypoxaemia and EDS are predictors of DM. BMI and AHI are predictors of pre-MD. (AU)

Diabetes y apnea obstructiva del sueño. Un estudio de casos y controles / Diabetes and obstructive sleep apnoea: A case-control study

Introducción La apnea obstructiva del sueño (AOS) y la diabetes mellitus (DM) son enfermedades muy prevalentes frecuentemente asociadas. Su coexistencia se asocia de forma independiente con un aumento de la prevalencia de comorbilidades cardiovasculares. Al existir un infradiagnóstico de esta asociación, es necesario optimizar la sospecha clínica mediante el estudio de predictores independientes de DM o de prediabetes (preDM) en pacientes con AOS. Método Estudio de casos y controles, seleccionados de manera aleatoria simple y emparejados por sexo, índice de masa corporal (IMC) y edad, que pretende estudiar la asociación de la AOS con la DM y la preDM e identificar factores predictores independientes para ambas enfermedades, en las personas con AOS. Resultados Incluimos 208 casos con AOS y 208 controles, sin AOS. En los primeros, el 18,8% tenían DM, por solo el 10,1% en los segundos (p=0,00). La prevalencia de preDM fue del 41,8% vs el 10,6%, respectivamente (p=0,00). Ciento veinticuatro casos (59,6%) refirieron excesiva somnolencia diurna (ESD) (escala Epworth, 10,5±3,1) vs el 24,5% del grupo control (escala Epworth, 6,6±2,9). El índice de apnea-hipopnea (IAH) y los índices de desaturación de O2 (IDO, CT90 y CT80) fueron significativamente mayores en el grupo de casos. El riesgo de presentar DM se relacionó con la edad, la hipoxemia nocturna y la ESD. El riesgo de presentar preDM, con el IMC y con el IAH. Conclusiones La AOS se asocia a la DM y a la preDM. La edad, la hipoxemia nocturna y la ESD son predictores de DM. El IMC y el IAH lo son de la preDM. (AU)

Introduction Obstructive sleep apnoea (OSA) and diabetes mellitus (DM) are very prevalent diseases frequently associated. Their coexistence is independently associated with an increased prevalence of cardiovascular comorbidities. As this association is underdiagnosed, it is necessary to optimise clinical suspicion by studying independent predictors of DM or prediabetes (preDM) in patients with OSA. Method A simple randomised case-control study, matched for sex, body mass index (BMI) and age, aimed to study the association of OSA with DM and preDM and to identify independent predictors for both diseases in people with OSA. Results We included 208 cases with OSA and 208 controls without OSA. In the former, 18.8% had DM compared to only 10.1% in the latter (P=.00). Prevalence of preDM was 41.8% vs. 10.6%, respectively (P=.00). One hundred and twenty-four cases (59.6%) reported excessive daytime sleepiness (EDS) (Epworth scale, 10.5±3.1) vs. 24.5% of the control group (Epworth scale, 6.6±2.9). Apnoea-hypopnoea index (AHI) and O2 desaturation indices (IDO, CT90 and CT80) were significantly higher in the case group. The risk of MD was related to age, nocturnal hypoxaemia and EDS. The risk of pre-MD was related to BMI and AHI. Conclusions OSA is associated with DM and preDM. Age, nocturnal hypoxaemia and EDS are predictors of DM. BMI and AHI are predictors of pre-MD. (AU)

Thrombotic risk assessed by PAI-1 in patients with COVID-19: The influence of hyperglycemia and diabetes mellitus.

OBJECTIVE: To assess thrombotic risk with PAI-1 levels in patients with COVID-19, to evaluate PAI-1 differences between hyperglycemic and/or Type 2 Diabetes Mellitus (T2DM) versus non-hyperglycemic patients, and to analyze the association of plasminogen activator inhibitor-1 (PAI-1) with hyperglycemia and T2DM. METHODS: A cross-sectional study carried out in 181 patients hospitalized for COVID-19. Two groups were formed: the patients with hyperglycemia at admission and/or previously diagnosed T2DM group and the non-hyperglycemic group. Fibrinolysis was assessed by measuring PAI-1 levels by ELISA. RESULTS: The mean age was 59.4±16.1 years; 55.8% were male 54.1% of patients presented obesity, 38.1% had pre-existing T2DM and 50.8% had admission hyperglycemia and/or pre-existing T2DM. The patients with admission hyperglycemia and/or preexisting T2DM had higher PAI-1 compared with non-hyperglycemic patients [197.5 (128.8-315.9) vs 158.1 (113.4-201.4) ng/mL; p=0.031]. The glucose levels showed a positive correlation with PAI-1 levels (r=0.284, p=0.041). A multivariate logistic regression analysis showed association of PAI-1 level and hyperglycemia and pre-existing T2DM with severity of COVID-19. CONCLUSION: Patients hospitalized for COVID-19 infection with preexisting T2DM or hyperglycemia detected during their hospitalization presented a greater increase in PAI-1 levels, which suggests that hyperglycemia contributes directly to the hypercoagulable state and probably a worse outcome from the patients.

Dairy product consumption and type 2 diabetes in an Argentinian population: is there an association?

Introduction: Introduction: dairy products have long been recommended as part of a healthy eating plan, but there is a controversial opinion about whether or not they should be included in the diet of people with type 2 diabetes (T2D). Objective: the aim of this study was to know if there is an association between the intake of total dairy and dairy subgroups and the chance of having T2D, and the status of markers of glucose metabolism. Methods: three hundred and forty-two adult subjects participated in the study. A validated food-frequency questionnaire was applied to establish the dairy intake. Clinical-pathological and anthropometric variables (height, weight, waist circumference and serum concentrations of blood glucose, glycated hemoglobin [HbA1c], high sensitive C-reactive protein [hs-CRP], tumor necrosis factor alpha [TNFα], interleukin [IL] 6 and IL-10) were measured. Consumption tertiles were calculated for each dairy subgroup. Correlation coefficients, multiple linear regression models and logistic regression models were used to assess the relation between dairy product consumption and markers of glucose metabolism. Results: a negative correlation was observed between the consumption of fermented dairy products and IL-10 (r = -0.27, p = 0.0206). Fermented dairy products were inversely associated with blood glucose, and HbA1c. Total dairy intake was positively associated with a lower chance of having diabetes in tertiles 2 and 3 of consumption, in relation to the reference tertile, adjusted for age, smoking habit, and alcohol intake, body mass index (BMI) and dietary variables. Conclusions: with this study, we broaden our understanding of the role of dairy intake in diabetes risk. However, more long-term studies are needed to confirm the associations and explore different confounding factors.

Introducción: Introducción: los lácteos se han recomendado durante mucho tiempo como parte de un plan de alimentación saludable, pero existen opiniones controvertidas sobre si deben incluirse en la dieta de las personas con diabetes tipo 2 (DT2). Objetivo: el objetivo fue conocer si existe asociación entre la ingesta de lácteos totales y subgrupos lácteos y la posibilidad de tener DT2, y el estado de los marcadores del metabolismo de la glucosa. Métodos: participaron 342 sujetos adultos. Se aplicó un cuestionario de frecuencia de consumo para establecer el consumo de lácteos. Se midieron variables clínicas-patológicas y antropométricas (talla, peso, circunferencia de cintura y concentraciones séricas de glucosa en sangre, hemoglobina glicosilada [HbA1c], proteína C reactiva ultrasensible [PCR-us], factor de necrosis tumoral alfa [TNFα], interleuquina [IL] 6 e IL-10). Se calcularon terciles de consumo para cada subgrupo de lácteos. Se utilizaron coeficientes de correlación, modelos de regresión lineal múltiple y regresión logística para evaluar la relación entre el consumo de lácteos y los marcadores del metabolismo de la glucosa. Resultados: los productos lácteos fermentados se asociaron inversamente con la glucosa en sangre y la HbA1c. La ingesta total de lácteos se asoció positivamente con una menor probabilidad de tener diabetes en los terciles 2 y 3 de consumo, en comparación con el tercil de referencia, ajustado por edad, tabaquismo, ingesta de alcohol, índice de masa corporal (IMC) y variables dietéticas. Conclusiones: con este estudio, ampliamos nuestra comprensión del papel de la ingesta de lácteos en el riesgo de diabetes. Sin embargo, se necesitan más estudios a largo plazo para confirmar las asociaciones y explorar diferentes factores de confusión.

[Diabetes and obstructive sleep apnoea: A case-control study]. / Diabetes y apnea obstructiva del sueño. Un estudio de casos y controles.

INTRODUCTION: Obstructive sleep apnoea (OSA) and diabetes mellitus (DM) are very prevalent diseases frequently associated. Their coexistence is independently associated with an increased prevalence of cardiovascular comorbidities. As this association is underdiagnosed, it is necessary to optimise clinical suspicion by studying independent predictors of DM or prediabetes (preDM) in patients with OSA. METHOD: A simple randomised case-control study, matched for sex, body mass index (BMI) and age, aimed to study the association of OSA with DM and preDM and to identify independent predictors for both diseases in people with OSA. RESULTS: We included 208 cases with OSA and 208 controls without OSA. In the former, 18.8% had DM compared to only 10.1% in the latter (P=.00). Prevalence of preDM was 41.8% vs. 10.6%, respectively (P=.00). One hundred and twenty-four cases (59.6%) reported excessive daytime sleepiness (EDS) (Epworth scale, 10.5±3.1) vs. 24.5% of the control group (Epworth scale, 6.6±2.9). Apnoea-hypopnoea index (AHI) and O2 desaturation indices (IDO, CT90 and CT80) were significantly higher in the case group. The risk of MD was related to age, nocturnal hypoxaemia and EDS. The risk of pre-MD was related to BMI and AHI. CONCLUSIONS: OSA is associated with DM and preDM. Age, nocturnal hypoxaemia and EDS are predictors of DM. BMI and AHI are predictors of pre-MD.

The role of trimethylamine-N-oxide level in the diagnosis of diabetic retinopathy and the differential diagnosis of diabetic and nondiabetic retinopathy / Papel do nível de N-óxido de trimetilamina no diagnóstico da retinopatia diabética e no diagnóstico diferencial da retinopatia diabética e não-diabética

ABSTRACT Purpose: Trimethylamine N-oxide serum levels have been associated with type 2 diabetes mellitus and its complications. The current study aimed to find out if plasma trimethylamine N-oxide level may be a novel marker in the diagnosis of diabetic retinopathy and if it can be used in the differential diagnosis of diabetic and nondiabetic retinopathy. Methods: The study included 30 patients with diabetic retinopathy, 30 patients with nondiabetic retinopathy, 30 patients with type 2 diabetes mellitus without retinopathy, and 30 healthy control participants. Biochemical parameters, serum IL-6, TNF-α, and trimethylamine N-oxide levels were measured in all participants. Results: Trimethylamine N-oxide level was significantly higher in diabetic retinopathy than in the other groups (p<0.001). There was no significant difference in trimethylamine N-oxide levels between nondiabetic retinopathy and control or type 2 diabetes mellitus Groups. There was a significant positive correlation between trimethylamine N-oxide level and elevated FPG, BMI, HOMA-IR score, BUN, IL-6, and TNF-α levels. Conclusion: The current study showed that the trimethylamine N-oxide level is elevated in diabetic retinopathy. These findings suggest that serum trimethylamine N-oxide level might be a novel marker for diabetic retinopathy, and it might be used in the differential diagnosis of diabetic and nondiabetic retinopathy.

RESUMO Objetivo: Os níveis séricos de N-óxido de trimetilamina têm sido associados ao diabetes mellitus tipo 2 e suas complicações. O presente estudo tem como objetivo responder a duas questões, entre elas: O nível plasmático de N-óxido de trimetilamina poderia ser um novo marcador no diagnóstico de retinopatia diabética? e Ele poderia ser utilizado no diagnóstico diferencial de retinopatia diabética e não diabética? Métodos: Trinta pacientes com retinopatia diabética, 30 pacientes com retinopatia não diabética, 30 pacientes com diabetes mellitus tipo 2 sem retinopatia e 30 participantes saudáveis do grupo controle foram incluídos no estudo. Parâmetros bioquímicos, níveis séricos de IL-6, de TNF-α e de N-óxido de trimetilamina foram medidos em todos os participantes. Resultados: O nível de N-óxido de trimetilamina foi significativamente maior na retinopatia diabética do que nos outros grupos (p<0,001). Não houve diferença significativa no nível de N-óxido de trimetilamina entre o grupo de retinopatia não diabética, do grupo controle ou do grupo de diabetes mellitus tipo 2. Houve uma correlação positiva significativa entre o nível de N-óxido de trimetilamina e os níveis elevados de FPG, IMC, HOMA-IR, BUN, IL-6 e TNF-α. Conclusão: O estudo atual mostrou que o nível de N-óxido de trimetilamina encontra-se elevado na retinopatia diabética. Esses achados sugerem que o nível sérico de N-óxido de trimetilamina pode ser um novo marcador na retinopatia diabética, podendo ser usado no diagnóstico diferencial de retinopatia diabética e não diabética.

Dynapenia and sarcopenia: association with the diagnosis, duration and complication of type 2 diabetes mellitus in ELSA-Brasil / Dinapenia e sarcopenia: associação com o diagnóstico, duração e complicações de diabetes mellitus tipo 2 no ELSA-Brasil / Dinapenia y sarcopenia: asociación con el diagnóstico, duración y complicaciones de la diabetes mellitus tipo 2 en ELSA-Brasil

Abstract: Sarcopenia (the loss of muscle mass, strength and skeletal muscle function) increases mortality and the risk of hospitalization in the older population. Although it is known that older adults with type 2 diabetes mellitus (T2DM) have a higher risk of dynapenia and sarcopenia, few studies have investigated these conditions in middle-aged populations. The objective of this study was to investigate whether T2DM, its duration, the presence of albuminuria, and glycemic control are associated with sarcopenia and its components in adults. The cross-sectional analysis was based on data from visit 2 of the Brazilian Longitudinal Study of Adult Health (2012-2014). The 2018 European Working Group on Sarcopenia in Older People criteria were used to define dynapenia, low appendicular muscle mass (LAMM), and sarcopenia (absent/probable/confirmed). The explanatory variables were: T2DM; duration of T2DM; T2DM according to the presence of albuminuria; and glycemic control (HbA1C < 7%) among people with T2DM. A total of 12,132 participants (mean age = 55.5, SD: 8.9 years) were included. The odds ratio for LAMM was greater among those with T2DM, T2DM duration from 5 to 10 years, and T2DM without albuminuria. Chances of dynapenia were higher among those with T2DM, T2DM duration > 10 years, and T2DM with and without albuminuria. The variables T2DM, T2DM ≥ 10 years, and T2DM with albuminuria increased the odds of probable sarcopenia, and T2DM duration from 5 to 10 years increased the odds of confirmed sarcopenia. The results support the importance of frequently monitoring the musculoskeletal mass and strength of individuals with T2DM to prevent sarcopenia and related outcomes.

Resumo: A sarcopenia (perda de massa muscular, força e função muscular esquelética) aumenta a mortalidade e o risco de hospitalização em idosos. Idosos com diabetes mellitus tipo 2 (DMT2) apresentam risco elevado de desenvolver dinapenia e sarcopenia, mas poucos estudos investigaram populações de meia-idade. O objetivo foi investigar se DMT2, sua duração, a presença de albuminúria e o controle glicêmico estão associados à sarcopenia e seus componentes em adultos. Análise transversal baseada nos dados da segunda visita do Estudo Longitudinal de Saúde do Adulto (2012-2014). Os critérios do European Working Group on Sarcopenia in Older People [Grupo de Trabalho Europeu sobre Sarcopenia em Pessoas Idosas] de 2018 foram usados para definir dinapenia, baixa massa muscular apendicular e sarcopenia (ausente/provável/confirmada). As variáveis explicativas foram: DMT2; duração do DMT2; DMT2 de acordo com a presença de albuminúria; e controle glicêmico (HbA1c < 7%) entre pessoas com DMT2. Foram incluídos 12.132 participantes (idade média de 55,5; DP: 8,9 anos). A razão de chances para baixa massa muscular apendicular foi maior entre pessoas com DMT2, duração do DMT2 entre 5 e 10 anos e DMT2 sem albuminúria. As chances de dinapenia foram maiores entre pessoas com DMT2, duração do DMT2 > 10 anos e DMT2 com e sem albuminúria. DMT2, DMT2 ≥ 10 anos e DMT2 com albuminúria aumentaram as chances de sarcopenia provável e duração do DMT2 entre 5 e 10 anos aumentaram as chances de sarcopenia confirmada. Os resultados reforçam a importância do monitoramento frequente da massa e da força muscular em indivíduos com DMT2 para prevenir a sarcopenia e desfechos relacionados.

Resumen: La sarcopenia (pérdida de masa muscular, fuerza y función muscular esquelética) aumenta la mortalidad y el riesgo de hospitalización en ancianos. Los ancianos con diabetes mellitus tipo 2 (DMT2) presentan un mayor riesgo de sufrir dinapenia y sarcopenia, pero pocos estudios han investigado poblaciones de mediana edad. El objetivo fue investigar si la DMT2, su duración, la presencia de albuminuria y el control glucémico están asociados con la sarcopenia y sus componentes en adultos. Análisis transversal basado en los datos de la visita 2 del Estudio Longitudinal de Salud del Adulto en Brasil (2012-2014). Se utilizaron los criterios del European Working Group on Sarcopenia in Older People [Grupo de Trabajo Europeo sobre Sarcopenia en Personas Mayores] del 2018 para definir dinapenia, baja masa muscular apendicular y sarcopenia (ausente/probable/confirmada). Las variables explicativas fueron las siguientes: DMT2; duración de la DMT2; DMT2 según la presencia de albuminuria; y control glucémico (HbA1c < 7%) entre personas con DMT2. Se incluyeron 12.132 participantes (edad media = 55,5, DE: 8,9 años). La razón de probabilidades de masa muscular apendicular baja fue mayor entre personas con DMT2, duración de la DMT2 entre 5 y 10 años y DMT2 sin albuminuria. Las probabilidades de dinapenia fueron mayores entre las personas con DMT2, duración de la DMT2 > 10 años y DMT2 con y sin albuminuria. Las condiciones de DMT2, DMT2 ≥ 10 años y DMT2 con albuminuria aumentaron las probabilidades de sarcopenia probable y la duración de la DMT2 entre 5 y 10 años las probabilidades de sarcopenia confirmada. Los resultados refuerzan la importancia del monitoreo frecuente de la masa y de la fuerza musculoesquelética en individuos con DMT2 para prevenir la sarcopenia y los desenlaces relacionados.

Identificación de factores determinantes de falta de adherencia a los antidiabéticos orales en pacientes con diabetes mellitus tipo 2: Revisión sistemática

Introducción: La adherencia al tratamiento antidiabético oral (ADO) en pacientes con Diabetes mellitus tipo 2 (DM2) se encuentra lejos de alcanzar las cifras deseables. Hay publicados multitud de trabajos que señalan factores que disminuyen la adherencia pero emplean distintas poblaciones y metodologías. Por tanto, el objetivo de esta revisión sistemática fue identificar y recopilar los factores que afectan a la falta de adherencia al tratamiento ADO en pacientes con DM2.Método: Las bases de datos utilizadas en la búsqueda bibliográfica fueron Medline (PubMed), Scopus, CINAHL y PsycINFO. Se consideraron estudios de casos-control, cohortes y ensayos clínicos aleatorizados realizados en per-sonas con DM2 y tratamiento ADO, donde se evaluaran factores determinantes de adherencia. El proceso de revi-sión fue realizado por dos investigadores de manera independiente en base a las recomendaciones Prisma.Resultados: De 11 publicaciones seleccionadas, dos fueron estudios de casos-control y nueve estudios de cohortes (siete retrospectivos). Las cifras de falta de adherencia oscilaron entre el 20,3-48 %. Resultaron factores asociados a la falta de adherencia a los ADOs: copago del paciente, dosis diaria de ADO, tipo de ADO prescrito, número de me-dicamentos prescritos, menor frecuencia de citas con el personal sanitario, niveles altos de HbA1C, depresión, sexo femenino, raza/etnia (distinta de la blanca), estado civil (distinto del matrimonio) y edad.Conclusiones: Desde un punto de vista clínico, es importante identificar qué factores de riesgo son modificables y así, los profesionales sanitarios podrán diseñar acciones para que los pacientes mejoren su adherencia al trata-miento ADO y el control de la DM2. (AU)

Introduction: Adherence to oral antidiabetic treatment (OAHA) in patients with type 2 Diabetes mellitus (T2DM) is far from reaching the desirable figures. A multitude of studies have been published on factors that influence non-ad-herence, although with different populations and methodologies. Therefore, the aim of this systematic review was identify and collect those factors that may influence non-adherence to OAHAs treatment in patients with T2DM.Method: The databases used in the literature search were Medline (PubMed), Scopus, CINAHL and PsycINFO. We considered case-control studies, cohorts and randomised clinical trials conducted in people with T2DM and OAHA treatment, where determinants of adherence were evaluated. The review process was conducted independently by two investigators based on Prisma recommendations.Results: Of 11 publications selected, two were case-control studies and nine were cohort studies (seven retrospec-tive). Non-adherence figures ranged from 20.3 to 48 %. Factors associated with non-adherence to OAHAs were found to be: patient co-payment, daily OAHA dose, type of OAHA prescribed, number of medications prescribed, less fre-quent appointments with healthcare staff, high HbA1C levels, depression, female sex, race/ethnicity (other than white), marital status (other than married) and age.Conclusions: From a clinical point of view, it is important to identify which risk factors are modifiable and thus, healthcare professionals will be able to design actions for patients to improve their adherence to OAHAs treatment as well as improve T2DM control. (AU)

Serum neuregulin 1 in relation to ventricular function and subclinical atherosclerosis in type 2 diabetes patients.

BACKGROUND AND AIMS: Neuregulin 1 (NRG-1) is one of the members of the epidermal growth factors proteins. The present study provides novel insights into the relationship between serum levels of NRG-1 and insulin resistance, subclinical atherosclerosis and cardiac dysfunction that occur in type 2 diabetes (T2D). METHODS: The study included 50 patients with T2D and 40 healthy age- and gender-matched controls. Serum NRG-1 was measured using ELISA. Glycemic parameters, lipid profile and insulin resistance were assessed. Trans-thoracic echocardiography and carotid intima media thickness (CIMT) were studied for all study subjects. RESULTS: T2D patients had significantly lower serum NRG-1 levels than controls. Serum NRG-1 was negatively correlated with age, fasting blood glucose, HbA1c, insulin resistance, blood urea, serum creatinine and LDL-C, and positively correlated with HDL-C, eGFR and CIMT. Regarding echocardiographic variables, serum NRG-1 was found to correlate positively with left ventricular global longitudinal strain and negatively with E/Ea ratio. NRG-1 was found to predict subclinical atherosclerosis in type 2 diabetes patients at a cut-off value<108.5pg/ml with 78% sensitivity and 80% specificity. CONCLUSIONS: A robust relationship was found between serum NRG-1 levels and hyperglycemia, insulin resistance, subclinical atherosclerosis, and cardiac dysfunction in patients with type 2 diabetes. These results shed light on a possible role of NRG-1 as a potential noninvasive biomarker for detection of cardiometabolic risk in T2D.

Food addiction behavior in patients with newly-diagnosed type 2 diabetes.

BACKGROUND: The concept of food addiction describes the difficulties of some individuals with regard to food consumption. OBJECTIVE: To determine the frequency of food addiction and its association with body mass index (BMI), calorie consumption and therapeutic control in patients with newly-diagnosed type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS: A total of 1,080 patients with T2DM were included. The degree of metabolic control was determined with the levels of glycated hemoglobin, low-density lipoprotein cholesterol and blood pressure. Daily caloric consumption was estimated with a semi-quantitative questionnaire of food consumption frequency. RESULTS: Nearly all patients showed overweight (40.5 %) and obesity (49.1 %). The frequency of food addiction was 54.2 % (56.9 % in women and 48.9 % in men). Food addiction was associated with BMI (OR = 1.89, p ≤ 0.05), high caloric intake (OR = 1.14, p ≤ 0.05) and glycated hemoglobin > 7 % (OR = 1.43, p ≤ 0.05). CONCLUSIONS: Food addiction is common in patients with overweight/obesity and newly-diagnosed T2DM, and is associated with higher-than-recommended caloric consumption, obesity degree and poor metabolic control.

ANTECEDENTES: El concepto de adicción a la comida describe las dificultades de algunos individuos respecto al consumo de comida. OBJETIVO: Determinar la frecuencia de la adicción a la comida y su asociación con el índice de masa corporal (IMC), consumo de calorías y control terapéutico en pacientes con diabetes mellitus tipo 2 (DMT2) de diagnóstico reciente. MATERIAL Y MÉTODOS: Se incluyeron 1080 pacientes con DMT2. Se determinó el grado de control terapéutico con niveles de hemoglobina glicada, colesterol de baja densidad y presión arterial. El consumo diario de calorías fue estimado con un cuestionario semicuantitativo de frecuencia de consumo de alimentos. RESULTADOS: Casi todos los pacientes mostraron sobrepeso (40.5 %) y obesidad (49.1 %). La frecuencia de adicción a la comida fue de 54.2 % (56.9 % en mujeres y 48.9 % en hombres). La adicción a la comida se asoció a IMC (RM = 1.89, p ≤ 0.05), alto consumo calórico (RM = 1.14, p ≤ 0.05) y hemoglobina glicada > 7 % (RM = 1.43, p ≤ 0.05). CONCLUSIONES: La adicción a la comida es frecuente en pacientes con sobrepeso/obesidad y DMT2 recientemente diagnosticada y se asocia al consumo calórico superior a lo recomendado, grado de obesidad y pobre control terapéutico.

Características clínicas y metabólicas en adultos con diabetes tipo 2 según la presencia de criterios diagnósticos de síndrome metabólico / Clinical and metabolic characteristics in adults with Type 2 diabetes according to the presence of diagnostic criteria for metabolic syndrome

Objetivo: determinar las características clínicas y metabólicas en adultos con diabetes tipo 2 según la presencia de criterios diagnósticos de síndrome metabólico (SM).Método: estudio descriptivo transversal con muestreo probabilístico aleatorio simple que incluyó a 49 pacientes con diabetes tipo 2. Se midió composición corporal, presión arterial y parámetros bioquímicos. Para determinar el diagnóstico de SM se aplicaron los criterios de la Federación Internacional de Diabetes. Se realizó análisis bivariante entre quienes presentaron criterios diagnósticos de SM y quienes no, utilizándose la prueba de contraste de hipótesis U de Mann Whitney.Resultados: la edad media de la muestra estudiada fue de 59,7 (DE: 11,5 años). La mayoría de los participantes fue mujer (65,3%) y con nivel socioeconómico medio (75,5%). La prevalencia de SM fue del 40% y la hiperglicemia fue la alteración más frecuente (93,3%). La mayoría de los pacientes con SM mostró, de manera estadísticamente significativa (p< 0,05), sobrepeso y obesidad, así como cifras más altas de índice de masa corporal, circunferencia de cintura, colesterol total, triglicéridos, glucosa, índices aterogénicos y tensión arterial.Conclusiones: los pacientes con DMT2 mostraron una alta prevalencia de SM. En los pacientes con SM, la hiperglicemia fue la alteración más frecuente, seguida de obesidad central medida por la circunferencia de cintura, y de acuerdo con su IMC, la mayoría presentó sobrepeso y obesidad. La media de triglicéridos, tensión arterial e índices aterogénicos fueron mayores en comparación con quienes no cumplían criterios diagnósticos de SM. (AU)

Objective: to determine the clinical and metabolic characteristics in adults with Type 2 diabetes according to the presence of diagnostic criteria for metabolic syndrome (MS).Method: a descriptive cross-sectional study with simple randomized probability sampling, including patients with Type 2 diabetes. There was measurement of body composition, blood pressure, and biochemical parameters. In order to determine the metabolic syndrome diagnosis, criteria by the International Diabetes Federation were applied. There was bivariate analysis among those who presented diagnostic criteria for SM and those who did not, using the Mann Whitney’s U test for hypothesis contrast.Results: the mean age of the sample studied was 59.7% (SD: 11.5 years). Most participants were female (65.3%) and with a middle socioeconomic level (75.5%). The prevalence of metabolic syndrome was 40%, and hyperglycaemia was the most frequent alteration (93.3%). The majority of patients with MS showed statistically significant overweight and obesity (p< 0.05), as well as higher figures of body mass index, waist circumference, total cholesterol, triglycerides, glucose, atherogenic indexes and blood pressure.Conclusions: patients with T2D showed a high prevalence of MS. In patients with MS, hyperglycaemia was the most frequent alteration, followed by central obesity measured by waist circumference; and according to their BMI, the majority presented overweight and obesity. The mean triglycerides, blood pressure and atherogenic indexes of these patients were higher vs. those who did not meet diagnostic criteria for MS. (AU)

NAFLD and type 2 diabetes: A practical guide for the joint management / Esteatosis hepática metabólica y diabetes mellitus tipo 2: Una guía práctica para el manejo conjunto

Non-alcoholic fatty liver disease (NAFLD) is becoming a major cause of liver disease-related morbidity, as well as mortality. Importantly, NAFLD is considered a mediator of systemic diseases including cardiovascular disease. Its prevalence is expected to increase, mainly due to its close association with obesity and type 2 diabetes mellitus (T2D). In addition, T2D and NAFLD share common pathophysiological mechanisms, and one can lead to or worsen the other. Therefore, a close collaboration between primary care physician, endocrinologists and hepatologists is essential to optimize the management of patients with NAFLD and T2D. Here, we summarize relevant aspects about NAFLD and T2D that all clinician managing these patients should know as well as current therapeutic options for the treatment of T2D associated with NAFLD. (AU)

La esteatosis hepática metabólica (EHmet) se está convirtiendo en una de las causas más importantes de morbimortalidad relacionada con las enfermedades hepáticas. Es importante destacar que la EHmet se considera un mediador de enfermedades sistémicas, incluidas las enfermedades cardiovasculares. Se espera que su prevalencia aumente, principalmente debido a su estrecha relación con la obesidad y la diabetes mellitus tipo 2 (DM2). Además, la DM2 y la EHmet comparten mecanismos fisiopatológicos comunes y una puede provocar o empeorar la otra. Por lo tanto, una estrecha colaboración entre el médico de atención primaria, endocrinólogos y hepatólogos es fundamental para optimizar el manejo de los pacientes con EHmet y DM2. En esta guía resumimos aspectos relevantes sobre EHmet y DM2 que todo médico que maneja a estos pacientes debe conocer, así como las opciones terapéuticas actuales para el tratamiento de DM2 asociada a EHmet. (AU)